Trial Profile
Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration for the Treatment of Hyperglycemia in Metformin Monotherapy Treated Type 2 Diabetic Patients: a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study.
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
- Sponsors Novartis
- 15 Mar 2012 This trial is discontinued in Great Britain, Hungary, Germany and has completed in Belgium.
- 17 Feb 2012 Actual patient number (556) added as reported by ClinicalTrials.gov.
- 17 Feb 2012 Additional trial locations added as reported by ClinicalTrials.gov.